Denmark · Medical and donor conditions

Unbranded microscope and specimen tubes in a clinical review room, illustrating medical and donor assessment

Denmark: medical and donor requirements in surrogacy cases

Scope and the short answer

Medical and donor rules in Denmark cannot be read as a stand-alone checklist for a surrogacy plan. First determine whether the proposed method falls within the scope of Danish assisted-reproduction law. As at 20 October 2026, §13 of the Danish Assisted Reproduction Act states that assisted reproduction must not take place where there is an agreement between the woman whose pregnancy is sought and another person that she will give birth to a child for that person. Section 1 defines the Act’s scope as assisted reproduction carried out by a health professional or under that professional’s responsibility in connection with treatment, diagnosis or research to establish pregnancy by a method other than sexual intercourse between a woman and a man; related tissue-centre activities are also covered. This is not a blanket ban on every conception method or every surrogacy agreement. That restriction is separate from the clinical age, consent and donor rules. This guide concerns treatment and gamete handling in Denmark; it does not establish that a particular surrogacy arrangement is lawful.

The central prohibition and the 2025 reform

Section 13 is the starting point for any plan involving a surrogate and treatment in Denmark. Its text contains no express exception for an altruistic agreement, a family relationship between the parties, a genetic link to an intended parent, or approval of an agreement under family law. Do not assume that an approved agreement gives a clinic permission to perform IVF, insemination or embryo transfer for the arrangement. Before booking or paying for treatment, obtain a written position from the clinic’s responsible clinician and independent Danish legal advice that addresses §13 specifically; a website, sales representative or verbal reassurance is not a legal determination. The Act’s penalty provision, §29(1), makes breaches of §13 punishable by a fine or imprisonment for up to four months. Section 29(2) excludes the gamete donor and the woman or couple who consent to ART from punishment under this Act; that exclusion does not make the procedure lawful.

From 1 January 2025, Danish family law has allowed parentage to be registered on the basis of an approved Danish altruistic surrogacy agreement, subject to statutory conditions. The agreement must be approved before the surrogate becomes pregnant. Among other requirements, the surrogate must be at least 25, resident in Denmark and have previously given birth; compensation is prohibited, and a genetic link to at least one intended parent is required. This is a parentage route. The 2024 parentage Act did not amend §13 of the Assisted Reproduction Act, so the two legal questions must be assessed separately.

Further approval conditions matter. The agreement must be altruistic and based on a close relationship between the surrogate and the intended parent(s). The surrogate must not be under guardianship or already pregnant when approval is sought. If she is married, in a registered partnership or cohabiting, her spouse or partner must also approve the agreement. No remuneration, including compensation for lost earnings, may be paid to the surrogate or her spouse or partner; actual pregnancy-related expenses may be reimbursed. Check the full current Family Law Agency requirements before relying on this route.

The rules at a glance

For a Danish clinical pathway, keep these rules distinct. First, §13 addresses the surrogacy agreement itself and bars assisted reproduction in that setting. Second, §6 prohibits assisted reproduction if the woman who will give birth is older than 45. Third, §5 regulates treatment using both donor sperm and donor eggs: both donations must be medically justified and at least one must be non-anonymous, subject to a narrow partner-egg-donation exception. Fourth, §5a prohibits treatment when the provider knows that the gametes come from specified genetically close relatives. Fifth, official donor guidance describes screening, infection testing and risk assessment, with details depending on donor type and how cells are handled. These rules are not interchangeable, and meeting one does not cure a problem under another. Binding tissue/cell rules, not guidance alone, govern donor selection and testing. Sections 6a–6b also provide a separate parental-capacity review where concerns arise.

Medical assessment and informed consent

Before ART, the woman receiving treatment should undergo a health assessment under official clinical guidance. Section 23 of the Act separately requires written consent from the woman and, where applicable, her spouse, registered partner or partner; consent must be based on oral and written information about the treatment’s effects, side effects and risks. The information should explain realistic chances of success for the specific treatment and individual factors, including age and combined fertility-related factors, rather than rely only on a general clinic success rate. Sections 6a and 6b create a separate assessment where there are concerns about the ability to care for a child after birth: for a patient or couple residing in Denmark, the responsible clinician must, with consent, refer the matter to the regional council; without consent, treatment must be refused. For a patient or couple not residing in Denmark, treatment must be refused if there is an obvious doubt about the ability to care for a child.

The regional council decides whether treatment may begin. It may involve other expertise with consent; if consent to that involvement is withheld, the council must refuse treatment. A decision under §6a(2) may be appealed to Ankestyrelsen (the Danish Appeals Board) within four weeks of the decision.

These medical, consent and parental-capacity safeguards apply generally to ART; they do not create an exception to §13. A medical opinion that treatment is safe, or a patient’s informed consent, is not by itself authority to perform a procedure otherwise prohibited.

The age ceiling: 45 is a statutory rule, not a clinic preference

Section 6 says assisted reproduction must not take place where the woman who will give birth is older than 45. The wording is a statutory ceiling: it is not merely a clinic’s preferred age range. The rule is framed around the person who will carry and give birth, not automatically around the age of an intended parent who will not gestate. The law’s “older than 45” wording should not be rewritten as “45 or older” without checking the facts and the applicable treatment date.

This ART ceiling must not be confused with the separate family-law condition that a woman entering an approved Danish altruistic surrogacy agreement must be at least 25 and have previously given birth. The minimum age and prior-birth condition belong to the agreement-approval framework; the 45-year ceiling belongs to ART. Neither rule removes the need to analyse §13 first.

Egg and sperm donation: the double-donation rule

Under §5, if the egg does not come from the woman who will give birth and the sperm does not come from her partner, assisted reproduction using both donated eggs and donated sperm is allowed only where use of both types of donor gametes is medically justified and either the sperm or the egg is donated on a non-anonymous basis. The condition applies to the combined donor arrangement, not simply to whether a clinic has found one donor medically suitable.

An amendment effective 1 January 2025 provides that the medical-justification requirement in §5(1) does not apply where the egg is donated by the partner of the woman who will give birth. That exception is specifically framed around the recipient’s partner. It should not be assumed to cover an intended parent who is not the carrier’s partner, and it does not override §13 where the treatment is connected with a surrogacy agreement. Ask the clinic to identify the exact legal basis for the proposed gamete combination.

Genetic relationships can be a legal bar

Section 5a prohibits assisted reproduction where a health professional, or someone working under that professional’s responsibility, knows that the egg and sperm come from genetically close or otherwise more closely related persons. It also prohibits treatment where either gamete comes from a same-sex relative in the direct ascending or descending line. These are statutory restrictions, not merely a clinic’s optional donor preference.

Disclose known biological relationships involving a proposed sperm or egg donor, including relevant family connections. Do not assume that a donor’s personal acquaintance with the intended parent is enough to establish whether the statutory restriction applies; the actual genetic relationship matters. Where the family tree is uncertain, ask the responsible clinician to document the relationship assessment before any treatment is considered. The prohibition on ART in a surrogacy arrangement remains a separate threshold issue.

Donor screening and infection testing

Binding Danish rules on human tissues and cells (Executive Order No. 58 of 18 January 2019, especially Annex 7) govern tissue-centre donor selection, assessment and mandatory testing; official guidance from 2015 supplements but does not replace those rules. For non-partner gamete donors, the regulation requires negative tests for HIV-1/2, hepatitis B and C, and syphilis; sperm donors must also test negative for chlamydia. Further tests may be required based on donor history, travel or exposure risks, and the characteristics of the cells.

The rules vary by donor category and handling. Annex 7 does not make its screening and laboratory-test criteria mandatory for partner gametes used directly without storage. Partner gametes that are processed or stored, or used for embryo cryopreservation, are subject to specified medical-justification and testing requirements. Non-partner egg and sperm donations are ordinarily quarantined for at least 180 days and the donor is retested, subject to the regulation’s defined alternatives, including certain additional nucleic-acid testing or validated inactivation. Ask the clinic or tissue establishment which provision applies, when samples must be taken, and whether repeat testing, quarantine and traceability requirements apply. A commercial bank’s package may exceed the legal minimum. These alternatives concern specified testing or sampling steps; they should not be treated as a blanket waiver of the quarantine period.

What screening can and cannot establish; law versus clinic policy

For non-partner gamete donations, Annex 7 also requires genetic screening for autosomal recessive genes considered prevalent in the donor’s ethnic background and an assessment of the risk of inherited conditions in the donor’s family, with the donor’s consent. The recipient must receive a clear explanation of identified risks and the precautions taken. Screening reduces risk; it cannot certify that a donor or future child is free from every transmissible or inherited condition. A family history may require an individual assessment or genetic counselling. Donor consent, accurate medical history, identity checks and traceable handling also matter; a short “screened” label is not a complete medical record.

Separate four sources of requirements: the Act, binding tissue/cell regulations, official clinical guidance, and the individual clinic’s own eligibility or laboratory policy. Ask for the written basis of any additional threshold concerning body mass index, ovarian reserve, previous pregnancy history, age below the statutory ceiling, or extra tests. Danish law sets no universal statutory BMI or AMH cut-off for every treatment type; that is a reason to request the exact provision or policy, not to assume either that a clinic rule is national law or that no other clinical rule exists.

Practical steps before committing to treatment

Before signing a treatment package or paying a deposit, ask the clinic in writing: (1) Is the procedure connected with an agreement that a woman will give birth for another person, and how does the clinic analyse §13? (2) Who is the responsible health professional, what health assessment is needed, and what written consent and information does §23 require? (3) Who will carry the pregnancy, and how does the §6 age rule apply on the proposed treatment date? (4) Which gametes will be used, who provides each one, and does §5 or the partner-egg exception apply? (5) What genetic relationships must be checked under §5a? (6) Which Annex 7 donor tests, sampling dates, quarantine, repeat-testing, storage and traceability rules apply? (7) Which extra criteria are binding law, official guidance or clinic policy? (8) Do §§6a–6b trigger a parental-capacity referral or refusal, and who makes that decision?

Request the proposed treatment plan, the clinic’s written legal position on the surrogacy issue, the donor-information and testing protocol, consent documents, and the relevant medical and family-history records. Keep the answers and versions of documents. If the clinic relies only on a verbal assurance that an altruistic agreement makes treatment permissible, pause and obtain independent Danish advice before proceeding.

If treatment is abroad; conclusion

If the procedure is performed outside Denmark, Danish domestic rules do not automatically become the rules governing every clinical act of the foreign clinic. The law of the treatment location and the clinic’s authorisation and donor protocols need separate review. Denmark’s rules on establishing or recognising parentage after a foreign surrogacy arrangement are a further, distinct question; recognition of parentage does not retroactively certify that the foreign treatment complied with Danish or local clinical law, nor does it guarantee donor-record access, nationality or travel documents.

The practical answer is therefore conditional: first determine where treatment will occur and whether it is linked to a surrogacy agreement; then analyse §13 before spending money on clinical eligibility. Only if the proposed treatment is legally available should the age, medical assessment, consent, gamete combination, genetic relationship and donor-screening rules be applied. Current clinic protocols and the latest consolidated legal texts should be checked before any real decision.

Official sources

Confirm the current legal text, clinical protocols and the facts of your case before treatment.

Last updated:

Author: Khachatrian Razmik, LL.M.

International surrogacy and parentage legal services — LEX SURROGACY by Lex Agency · Author profile · Editorial standards